Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

AbCellera Biologics

Biotech & Life Sciences · Vancouver, Canada · Founded 2012 · IPO 2020 Unicorn

Innovator in antibody discovery for therapeutics, and immune profiling for vaccine research

Valuation
$879M
Market cap · May/2026
Revenue
$75M
Latest reported FY

Investors

8 investors on AbCellera Biologics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 7 investors entered at this stage
Viking Global Investors
Northview LifeSciences
OrbiMed
Eli Lilly
Peter Thiel
Presight Capital
The University of British Columbia

Global footprint

Where AbCellera Biologics has talent and traffic

AI talent share
3.8% of workforce is AI talent
(22 of 576 staff)
Core AI81.39%
Other AI142.43%
Non-AI workforce55496.18%
Workforce by country
8 countries with
team presence
🇨🇦 Canada82%
🇦🇺 Australia9.8%
🇺🇸 United States5.7%
🇮🇪 Ireland1.3%
🇮🇳 India0.6%
Top 5 of 8 shown
Web traffic by country
30K monthly visits
across markets
🇨🇦 Canada46.7%
🇺🇸 United States18.3%
🏳️ Korea10%
🏳️ Republic of7.3%
🇮🇳 India5.7%
Top 5 markets shown

Patent intelligence

$63M patent portfolio · 45 active families

Estimated portfolio value
$63M
7.2% of market cap · 3.5× smaller than top peer Ganymed Pharmaceuticals ($223M)
45 active patent families
Where AbCellera Biologics innovates DiseaseMolecular biologyAntiendomysial antibodiesImmunologyBioinformatics

Where AbCellera Biologics concentrates vs peers

Each axis is a top-10 topic across AbCellera Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

AbCellera Biologics's 5 investments and acquisitions.

Every disclosed deal where AbCellera Biologics appeared as a backer or acquirer, 2020–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across AbCellera Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        AbCellera Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        5 of 5 deals

        Market sentiment

        What the market is saying about AbCellera Biologics

        An AI-synthesized read of the highest-engagement posts about AbCellera Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See AbCellera Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.